Allen Seylani: Impact of a Treat-to-Target Urate-Lowering Strategy on Cardiovascular Events
Allen Seylani, Scientific Reviewer at Oxford University Press, Resident Physician at Cleveland Clinic, shared a post on LinkedIn about a recent article by Pascal Richette et al. published in JAMA Internal Medicine:
“A new study in JAMA Internal Medicine followed over 100,000 patients with gout and asked a simple but powerful question.
Does treating to a serum urate target below 6 mg/dL actually change cardiovascular outcomes.
The answer appears to be yes.
Patients who achieved target urate levels had a significantly lower risk of major cardiovascular events within 5 years compared with those who did not.
Fewer flares were expected. Fewer heart attacks and strokes were not.
This matters because it reframes gout from a nuisance disease to a systemic inflammatory condition with real cardiovascular consequences. It also challenges us as clinicians and researchers to stop thinking of urate lowering as a checkbox and start thinking of it as disease modification.
The most striking part to me is not just the association, but the implication. Inflammation, not urate alone, may be the missing link connecting gout to cardiovascular risk. Treating to target likely works because it quiets chronic inflammation, reduces flare related inflammatory surges, and stabilizes the system as a whole.
And yet, fewer than one third of patients actually reached target urate levels within a year.
That gap between evidence and practice is where leadership lives.
This is where better care models, tighter follow up, patient education, and accountability can change outcomes at scale. It is also where translational thinking matters, connecting population data, molecular inflammation, and bedside decisions.
Gout is no longer just about pain control. It is about prevention, longevity, and systems level thinking.
Curious how others are integrating treat to target strategies into real world practice, and how we can do better for patients who are still being left behind.”
Title: Urate Lowering and Cardiovascular Risk—Extending the Benefits of a Treat-to-Target Strategy in Gout
Authors: Pascal Richette, Augustin Latourte, Hang-Korng Ea
Read the Full Article on JAMA Internal Medicine
Stay updated with Hemostasis Today.
-
Mar 22, 2026, 17:21Arrigo Francesco Giuseppe Cicero: Diagnostic and Prognostic Perspectives of Glycocalyx Disruption in Pregnancy
-
Mar 22, 2026, 17:19Veronica Sanchez: Stress from Pregnancy Complications Impacts The Long-Term Cardiovascular Health
-
Mar 22, 2026, 16:21Ala Eddin Sagar: Apixaban vs Rivaroxaban on This Week in Pulmonary and Critical Care Medicine
-
Mar 22, 2026, 16:14Andre W. Bourgoyne: Anemia Management as a Comprehensive Hospital Performance Strategy
-
Mar 22, 2026, 16:03Fibrinogen-Guided Management of Postpartum Hemorrhage – Transfusion Medicine KMC Manipal
-
Mar 22, 2026, 15:48Simon Senanu: Diagnostic Significance of Target Cells in Peripheral Blood Smear
-
Mar 22, 2026, 15:43Hayley Evans: What If The Decision Support System Is Part of The Problem?
-
Mar 22, 2026, 15:29Archit Pandharipande: The Burden and Impact of Heavy Menstrual Bleeding in Adolescents with Bleeding Disorders
-
Mar 22, 2026, 15:17Mamtha Balla: Mastering the Lab and Clinical Connection in Hemostasis and Thrombosis